Effects of nicotinic acid and lovastatin in combination with cholestyramine in renal transplant patients.
We assessed the short and long-term efficacy and safety of the lipid lowering drugs, nicotinic acid, and the HMG-CoA reductase inhibitor, lovastatin, in combination with cholestyramine in four renal transplant patients. Combination therapy with cholestyramine failed to lower the TC and LDL to the levels recommended by the NCEP guidelines.
Lal
Sunder M
SM
Department of Internal Medicine, University of Missouri-Columbia, USA.
Katyal
Atul
A
D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D002792:Cholestyramine Resin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000628:therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008148:Lovastatin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D002792:Cholestyramine Resin; D009525:Niacin; D002784:Cholesterol; D008148:Lovastatin